These effects were achieved through the regulation of the Akt/mTOR/GSK-3β signaling pathway, positioning ESP as a promising therapeutic agent for addressing cognitive decline associated with AD (Luo et al., 2022). The gene discussed is AKT1; the disease is Alzheimer disease.